When T cell expansion experiments are so absolutely dependent on IL-2, what exactly defines the "potency" of recombinant protein?

Author: Senior Product Manager of UA Views：9

Interleukin-2 is the core driving factor for clonal expansion and survival of T lymphocytes, and its performance in in vitro experiments directly determines whether cell therapy, immune response analysis, and functional assays can obtain stable readings.

Recent Advances
Product Information

Recent Advances

When T Cell Expansion Experiments Are So Absolutely Dependent on IL-2, What Exactly Defines the “Potency” of a Recombinant Protein?

Summary: Interleukin-2 is the core driving factor for clonal expansion and survival of T lymphocytes, and its performance in in vitro experiments directly determines whether cell therapy, immune response analysis, and functional assays can yield stable readouts. However, the activity determination of recombinant human IL-2 cannot be encompassed by a single purity metric: the choice of expression system shapes the post-translational state of the product, specific activity and endotoxin levels together define the cleanliness of the signaling window, and tag strategies may inadvertently alter the kinetics of receptor binding.

I. The identity of IL-2 carries an inherent paradox.

When interleukin-2 (IL-2) was first discovered, it was defined as a “T cell growth factor” capable of sustaining long-term T cell proliferation in vitro. This naming precisely captured its central role in clonal expansion experiments, yet failed to foresee the complexity revealed by subsequent research. The functional landscape of IL-2 is not unidirectional immune enhancement: it simultaneously drives the expansion and survival of effector T cells while also maintaining the suppressive capacity of regulatory T cells (Tregs). Both functions share the same receptor yet lead to opposite immunological outcomes. Part of the explanation for this paradox lies in the hierarchical differences in receptor affinity: the high-affinity receptor (composed of IL-2Rα, β, and γ chains) primarily mediates effector signaling, while the intermediate-affinity receptor (the βγ dimer alone) participates in Treg maintenance under specific contexts.

For in vitro experiments, the practical implication of this functional duality is that what the added concentration and duration of IL-2 shape is not a uniform “immune activation” state, but rather a dynamic equilibrium determined by the receptor expression profile of target cells and the composition of the culture system. In T cell expansion protocols, if the potency of IL-2 is lower than expected, cells may undergo activation-induced apoptosis rather than sustained proliferation; if batch-to-batch activity fluctuations go undetected, differences between experimental groups may be systematically attributed to treatment conditions rather than to the reagent itself. Therefore, discussing the quality of recombinant IL-2 first requires acknowledging that its activity performance cannot be defined in isolation from the specific cellular context.

II. How the choice of expression system shapes the functional character of the product.

The mature region of recombinant human IL-2 spans Ala21-Thr153, with a theoretical molecular weight of approximately 15.5 kDa. The E. coli expression system produces a non-glycosylated form of the product, appearing as a single band at approximately 15 kDa under SDS-PAGE reducing conditions. This form can meet the needs of most T cell proliferation and functional assay experiments, because IL-2 receptor binding and signal activation do not depend on the presence of glycan chains. However, when experimental designs involve analyses sensitive to post-translational modifications——such as when parallel comparison with native-source IL-2 is required, or when examining the effects of glycosylation on receptor binding kinetics——the behavior of the non-glycosylated product may show detectable deviations from the physiological state.

IL-2 produced by eukaryotic expression systems presents a different apparent molecular weight profile: due to glycosylation modifications, it may migrate as bands at 17 to 19 kDa or as double bands on SDS-PAGE. This difference itself is not a judgment of superiority or inferiority, but rather points to different experimental applications. For studies read out by receptor binding affinity or in vivo half-life, the proximity of glycosylation status has reference value; for routine functional experiments read out by cell proliferation inhibition or STAT5 phosphorylation, E. coli-derived non-glycosylated IL-2 has clear advantages in batch consistency and cost accessibility. The key to selection is not which one is “better,” but whether the product form matches the experimental question.

III. Specific activity and endotoxin: two parameters that jointly define the “signal-to-noise ratio.”

Specific activity is expressed as ED50 values or international units (IU). For human IL-2, the CTLL-2 or Kit225 cell proliferation assay is commonly used for determination, and there are differences in how activity is labeled among products from different sources: some manufacturers present it as ED50 (ng/mL), while others label it as IU/mg. These two expressions are not in a simple conversion relationship, because the assignment of IU depends on specific international reference standards. When researchers compare the potency of IL-2 across batches or sources, if the consistency of the assay system has not been confirmed, differences between values may reflect methodological shifts rather than changes in the activity of the product itself.

Endotoxin levels carry particular weight in IL-2-related experiments. Although the core target cells of IL-2——T lymphocytes——do not respond to lipopolysaccharide as dramatically as myeloid cells, monocytes or dendritic cells often present in the culture system can be activated through the TLR4 pathway, thereby secreting endogenous cytokines that alter the activation state of T cells. When IL-2 is used in stimulation experiments with peripheral blood mononuclear cells (PBMCs) or in mixed lymphocyte reactions, interference through this indirect pathway deserves particular vigilance. The practical significance of products labeled with endotoxin below 0.1 EU/μg is that this indirect contribution is compressed to a negligible background level, allowing readouts of T cell expansion or activation markers to be more cleanly attributed to IL-2 signaling itself.

IV. Tag strategy and formulation buffer: easily overlooked variables.

Tag-free design has clear experimental rationale in IL-2 products. Although His tags or Fc tags facilitate purification and detection, the tag sequence may occupy or be adjacent to the receptor binding interface, altering the docking kinetics of IL-2 with IL-2Rα. For experiments aimed at quantifying receptor occupancy or signal intensity, tag-free products avoid the enzymatic cleavage residues that may be introduced during tag removal, and also eliminate the potential contribution of the tag itself as an additional epitope to the readout. Furthermore, the buffer system composition of lyophilized powder also affects behavior after reconstitution: the stabilizing effect of trehalose-containing formulations on protein conformation during lyophilization and reconstitution has been supported by considerable literature, while the type of buffer salt and pH relate to compatibility with the culture system after reconstitution.

V. Conclusion.

The IL-2 Protein, Human (UA040108) provided by UniAI uses an E. coli expression system, with the expressed sequence covering the Ala21-Thr153 mature region, a theoretical molecular weight of 15.5 kDa, consistent with the human IL-2 mature monomer reported in the literature. The product expressed in E. coli is in non-glycosylated form. For IL-2, glycosylation modification is not a necessary condition for receptor binding and signal activation, and the non-glycosylated recombinant protein can meet the needs in T cell proliferation experiments and STAT5 phosphorylation validation.

Purity is determined by SDS-PAGE to be greater than 95%, and endotoxin is labeled below 0.1 EU/μg. The tag-free design avoids potential steric interference of the tag sequence with the receptor binding interface, and also eliminates enzymatic cleavage residues that may be introduced during tag removal. This configuration provides a controllable-background starting point for activity determination using CTLL-2 or Kit225 cell systems, T cell expansion protocols starting from PBMCs, and use as an additive component in CAR-T or TIL preparation workflows. Researchers should still establish dose-response curves in their own experimental systems to confirm that batch-specific activity falls within the expected response range.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UNIV Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next